Paper No. ___
`Filed: April 12, 2022
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________________
`
`MYLAN PHARMACEUTICALS, INC., CELLTRION, INC., and
`APOTEX, INC.,
`Petitioners,
`
`v.
`
`REGENERON PHARMACEUTICALS, INC.,
`Patent Owner.
`
`_____________________________
`
`IPR2021-008801
`Patent No. 9,669,069
`
`_____________________________
`
`PETITIONER UPDATED EXHIBIT LIST
`
`1 IPR2022-00257 has been joined with this proceeding.
`
`
`Filed: April 12, 2022
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________________
`
`MYLAN PHARMACEUTICALS, INC., CELLTRION, INC., and
`APOTEX, INC.,
`Petitioners,
`
`v.
`
`REGENERON PHARMACEUTICALS, INC.,
`Patent Owner.
`
`_____________________________
`
`IPR2021-008801
`Patent No. 9,669,069
`
`_____________________________
`
`PETITIONER UPDATED EXHIBIT LIST
`
`1 IPR2022-00257 has been joined with this proceeding.
`
`
`
`Exhibit
`No.
`1001
`
`Description
`
`U.S. Patent No. 9,669,069 B2 (“’069 patent”)
`
`1002
`
`Expert Declaration of Dr. Thomas A. Albini in Support of Petition for
`
`Inter Partes Review of Patent No. 9,669,069 B2, dated May 4, 2021
`
`(“Albini”)
`
`1003
`
`Expert Declaration of Mary Gerritsen, Ph.D. in Support of Petition
`
`for Inter Partes Review of U.S. Patent No. 9,669,069 B2, dated Apr.
`
`26, 2021(“Gerritsen”)
`
`1004
`
`1005
`
`1006
`
`1007
`
`Jocelyn Holash et al., VEGF-Trap: A VEGF Blocker with Potent
`Antitumor Effects, 99 PROC. NAT’L ACAD. SCI. 11393 (2002)
`(“Holash”)
`
`Quan Dong Nguyen et al., A Phase I Study of Intravitreal Vascular
`Endothelial Growth Factor Trap-Eye in Patients with Neovascular
`Age-Related Macular Degeneration, 116 OPHTHALMOLOGY 2141
`(2009) (“Nguyen-2009”)
`
`James A Dixon et al., VEGF Trap-Eye for the Treatment of
`Neovascular Age-Related Macular Degeneration, 18 EXPERT
`OPINION ON INVESTIGATIONAL DRUGS 1573 (2009) (“Dixon”)
`
`Adis R&D Profile, Aflibercept: AVE 0005, AVE 005, AVE0005,
`VEGF Trap – Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye, 9
`DRUGS R&D 261 (2008) (“Adis”)
`
`1008
`
`U.S. Patent No. 7,531,173 B2 (“’173 patent”)
`
`-2-
`
`
`
`1009
`
`U.S. Patent No. 7,396,664 B2 (“’664 patent”)
`
`1010
`
`U.S. Patent No. 7,374,758 B2 (“’758 patent”)
`
`1011
`
`1012
`
`1013
`
`1014
`
`F Semeraro et al., Aflibercept in Wet AMD: Specific Role and
`Optimal Use, 7 DRUG DESIGN, DEV. & THERAPY 711 (2013)
`(“Semeraro”)
`
`Press Release, Regeneron, Regeneron and Bayer Health Care
`Announce Encouraging 32-Week Follow-Up Results from a Phase 2
`Study of VEGF Trap-Eye in Age-Related Macular Degeneration
`(Apr. 28, 2008),
`http://investor.regeneron.com/releasedetail.cfm?releaseid=394066
`(“Regeneron (28-April-2008)”)
`
`Press Release, Regeneron, Bayer and Regeneron Dose First
`Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-
`Related Macular Degeneration (May 8, 2008),
`http://investor.regeneron.com/releasedetail.cfm?ReleaseID=394065
`(“Regeneron (8-May-2008)”)
`
`Vascular Endothelial Growth Factor (VEGF) Trap-Eye:
`Investigation of Efficacy and Safety in Wet Age-Related Macular
`Degeneration (AMD) (VIEW1), NCT00509795, ClinicalTrials.gov
`(Apr. 28, 2009), https://clinicaltrials.gov/ct2/show/NCT00509795
`(“NCT-795”)
`
`1015
`
`VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD
`(VIEW 2), NCT00637377, ClinicalTrials.gov (Mar. 17, 2008),
`https://clinicaltrials.gov/ct2/show/NCT00637377 (“NCT-377”)
`
`1016
`
`U.S. Patent Nos. 7,303,746 B2; 7,303,747 B2; 7,306,799 B2; and
`7,521,049 B2 (“Monthly-Dosing-Patents”)
`
`1017
`
`File History of U.S. Patent No. 9,669,069 B2 (“’069 FH”)
`
`1018
`
`Jeffrey S. Heier et al., Intravitreal Aflibercept (VEGF Trap-Eye) in
`Wet Age-Related Macular Degeneration, 119 OPHTHALMOLOGY
`
`-3-
`
`
`
`2537 (2012) (“Heier-2012”)
`
`1019
`
`U.S. Patent No. 9,254,338 B2 (“’338 patent”)
`
`1020
`
`Jeffrey S. Heier, Intravitreal VEGF Trap for AMD: An Update,
`
`RETINA TODAY, Oct. 2009, 44 (“Heier-2009”)
`
`1021
`
`Regeneron Pharm., Inc., Quarterly Report (Form 10-Q) (Sept. 30,
`
`2009) (“2009 10-Q”)
`
`1022
`
`U.S. Patent No. 7,374,757 B2 (“’757 patent”)
`
`1023
`
`U.S. Patent No. 7,070,959 B1 (“’959 patent”)
`
`1024
`
`File History of U.S. Patent No. 7,374,758 B2, 12/22/2011 Patent
`
`Term Extension Application (“’758 FH, 12/22/2011 PTE”)
`
`1025 Michael Engelbert et al., Long-Term Follow-Up For Type 1
`(Subretinal Pigment Epithelium) Neovascularization Using A
`Modified “Treat And Extend” Dosing Regimen of Intravitreal
`Antivascular Endothelial Growth Factor Therapy, 30 RETINA, J.
`RETINAL & VITREOUS DISEASES 1368 (2010) (“Engelbert-2010”)
`
`1026 Michael Engelbert et al., “Treat and Extend” Dosing of Intravitreal
`Antivascular Endothelial Growth Factor Therapy For Type 3
`Neovascularization/Retinal Angiomatous Proliferation, 29 J.
`RETINAL & VITREOUS DISEASES 1424 (2009) (“Engelbert-2009”)
`
`1027
`
`Richard F. Spaide et al., Prospective Study of Intravitreal
`
`Ranibizumab as a Treatment for Decreased Visual Acuity Secondary
`
`-4-
`
`
`
`to Central Retinal Vein Occlusion, 147 AM. J. OPHTHALMOLOGY
`
`298 (2009) (“Spaide”)
`
`1028
`
`1029
`
`1030
`
`Press Release, Regeneron, Bayer and Regeneron Extend
`Development Program for VEGF Trap-Eye to Include Central
`Retinal Vein Occlusion (Apr. 30, 2009),
`https://investor.regeneron.com/news-releases/news-release-
`details/bayer-and-regeneron-extend-development-program-vegf-
`trap-eye (“Regeneron (30-April-2009)”)
`
`Vascular Endothelial Growth Factor (VEGF) Trap-Eye:
`Investigation of Efficacy and Safety in Central Retinal Vein
`Occlusion (CRVO), NCT01012973, ClinicalTrials.gov (Nov. 12,
`2009), https://clinicaltrials.gov/ct2/show/NCT01012973 (“NCT-
`973”)
`
`P Mitchell et al., Ranibizumab (Lucentis) in Neovascular Age-
`Related Macular Degeneration: Evidence from Clinical Trials, 94
`BRIT. J. OPHTHALMOLOGY 2 (2009) (date of online publication)
`(“Mitchell”)
`
`1031
`
`Pascale G. Massin, Anti-VEGF Therapy for Diabetic Macular
`
`Edema: An Update, RETINA TODAY, SEPT./Oct. 2008, 54
`
`(“Massin”)
`
`1032
`
`Press Release, Bayer AG, Bayer and Regeneron Start Additional
`Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular
`Degeneration (May 8, 2008) (“Bayer (8-May-2008)”)
`
`1033
`
`U.S. Patent Application Publication No. 2006/0217311 A1 (“Dix”)
`
`-5-
`
`
`
`1034
`
`1035
`
`1036
`
`1037
`
`Anne E. Fung et al., An Optical Coherence Tomography-Guided,
`Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis)
`for Neovascular Age-related Macular Degeneration, 143 AM. J.
`OPHTHALMOLOGY 566 (2007) (“Fung”)
`
`Geeta A. Lalwani et al., A Variable-dosing Regimen with
`Intravitreal Ranibizumab for Neovascular Age-Related Macular
`Degeneration: Year 2 of the PrONTO Study, 148 AM. J.
`OPHTHALMOLOGY 43 (2009) (“Lalwani”)
`
`Peter A Campochiaro et al., Ranibizumab for Macular Edema Due
`to Retinal Vein Occlusions: Implication of VEGF as a Critical
`Stimulator, 16 MOLECULAR THERAPY 791 (2008) (“Campochiaro”)
`
`Robert Steinbrook, The Price of Sight — Ranibizumab, Bevacizumab,
`and the Treatment of Macular Degeneration, 355 N. ENG. J. MED.
`1409 (2006) (“Steinbrook”)
`
`1038
`
`Curriculum Vitae of Dr. Thomas Albini (“Albini CV”)
`
`1039
`
`U.S. Patent No. 7,378,095 B2 (“’095 patent”)
`
`1040
`
`1041
`
`1042
`
`International Nonproprietary Names for Pharmaceutical
`Substances (INN), 20 WHO DRUG INFORMATION 115 (2006)
`(“WHO Drug Info”)
`
`Press Release, Regeneron, Regeneron Reports Full Year and Fourth
`Quarter 2008 Financial and Operating Results (Feb. 26, 2009),
`https://investor.regeneron.com/news-releases/news-release-
`details/regeneron-reports-full-year-and-fourth-quarter-2008-
`financial (“Regeneron (26-February-2009)”)
`
`U.S. DEP’T HEALTH & HUMAN SERVS., NAT’L INST. HEALTH, NAT’L
`EYE INST., Age-Related Macular Degeneration: What You Should
`Know (Sept. 2015),
`https://www.nei.nih.gov/sites/default/files/health-pdfs/WYSK
`AMD English Sept2015 PRINT.pdf (“NIH AMD”)
`
`-6-
`
`
`
`1043
`
`1044
`
`1045
`
`1046
`
`1047
`
`David M. Brown & Carl D. Regillo, Anti-VEGF Agents in the
`Treatment of Neovascular Age-Related Macular Degeneration:
`Applying Clinical Trial Results to the Treatment of Everyday
`Patients, 144 AM. J. OPHTHALMOLOGY 627 (2007) (“Brown”)
`
`U.S. DEP’T HEALTH & HUMAN SERVS., NAT’L INST. HEALTH, NAT’L
`EYE INST., Diabetic Retinopathy: What You Should Know (Sept.
`2015), https://www.nei.nih.gov/sites/default/files/2019-06/Diabetic-
`Retinopathy-What-You-Should-Know-508.pdf (“NIH DR”)
`
`Napoleone Ferrara & Kari Alitalo, Clinical Applications of
`Angiogenic Growth Factors and Their Inhibitors, 5 NATURE MED.
`1359 (1999) (“Ferrara-1999”)
`
`Napoleone Ferrara & Robert S. Kerbel, Angiogenesis as a
`Therapeutic Target, 438 NATURE 967 (2005) (“Ferrara-2005”)
`
`Ziad F. Bashshur et al., Intravitreal Bevacizumab for the
`Management of Choroidal Neovascularization in Age-Related
`Macular Degeneration, 142 AM. J. OPHTHALMOLOGY 1 (2006)
`(“Bashshur”)
`
`1048
`
`LUCENTIS® Prescribing Information (2006) (“Lucentis”)
`
`1049
`
`L. Spielberg & A. Leys, Intravitreal Bevacizumab for Myopic
`Choroidal Neovascularization: Short-Term and 1-Year Results, 312
`BULLETIN SOCIETE BELGE D’OPHTALMOLOGIE 17 (2009)
`(“Spielberg”)
`
`1050
`
`Ursula Schmidt-Erfurth, Current Concepts in the Management of
`
`Diabetic Macular Edema, 7 PROCEEDINGS 52 (2010) (“Schmidt-
`
`Erfurth”)
`
`-7-
`
`
`
`1051
`
`1052
`
`1053
`
`1054
`
`1055
`
`1056
`
`Pearse A. Keane et al., Effect of Ranibizumab Retreatment Frequency
`on Neurosensory Retinal Volume in Neovascular AMD, 29 RETINA
`592 (2009) (“Keane”)
`
`J.S. Rudge et al., VEGF Trap as a Novel Antiangiogenic Treatment
`Currently in Clinical Trials for Cancer and Eye Diseases, and
`VelociGene®-Based Discovery of the Next Generation of
`Angiogenesis Targets, 70 COLD SPRING HARBOR SYMPOSIA
`QUANTITATIVE BIOLOGY 411 (2005) (“Rudge”)
`
`Press Release, Regeneron, Positive Interim Phase 2 Data Reported
`for VEGF Trap-Eye in Age-Related Macular Degeneration (Mar.
`27, 2007), https://newsroom.regeneron.com/news-releases/news-
`release-details/positive-interim-phase-2-data-reported-vegf-trap-
`eye-age-related?releaseid=394105 (“Regeneron (27-March-
`2007)”)
`
`Press Release, Regeneron, Regeneron and Bayer Healthcare Initiate
`Phase 3 Global Development Program for VEGF Trap-Eye in Wet
`Age-Related Macular Degeneration (AMD) (Aug. 2, 2007),
`https://investor.regeneron.com/news-releases/news-release-
`details/regeneron-and-bayer-healthcare-initiate-phase-3-global
`(“Regeneron (2-August-2007)”)
`
`Retina Society, VEGF Trap-Eye in Wet AMD CLEAR-IT 2:
`Summary of One-Year Key Results, A Phase 2, Randomized,
`Controlled Dose-and Interval-Ranging Study of Intravitreal VEGF
`Trap-Eye in Patients With Neovascular, Age-Related Macular
`Degeneration (Sept. 28, 2008) (“Retina Society Meeting
`Presentation”)
`
`Press Release, Regeneron, VEGF Trap-Eye Final Phase 2 Results in
`Age-related Macular Degeneration Presented at 2008 Retina Society
`Meeting (Sept. 28, 2008), https://investor.regeneron.com/news-
`releases/news-release-details/vegf-trap-eye-final-phase-2-results-
`age-related-macular?ReleaseID=393906 (“Regeneron (28-
`September-2008)”)
`
`-8-
`
`
`
`1057
`
`1058
`
`1059
`
`1060
`
`Press Release, Regeneron, VEGF Trap-Eye Shows Positive Results
`in a Phase 2 Study in Patients with Diabetic Macular Edema (Feb.
`18, 2010), https://investor.regeneron.com/news-releases/news-
`release-details/vegf-trap-eye-shows-positive-results-phase-2-study-
`patients?releaseid=445521 (“Regeneron (18-February-2010)”)
`
`ASS’N FOR RES. VISION & OPHTHALMOLOGY, ARVO® News
`(Winter/Spring 2008) (“ARVONews Winter/Spring 2008”)
`
`ASS’N FOR RES. VISION & OPHTHALMOLOGY, ARVO® News
`(Summer 2007) (“ARVONews Summer 2007”)
`
`Jean-François Korobelnik et al., Intravitreal Aflibercept Injection for
`Macular Edema Resulting from Central Retinal Vein Occlusion, 121
`OPHTHALMOLOGY 202 (2014) (“Korobelnik”)
`
`1061
`
`Curriculum Vitae of Dr. Mary Gerritsen (“Gerritsen CV”)
`
`1062
`
`EP 2 663 325 (published as WO 2012/097019 (A1)) (“EP-325”)
`
`1063
`
`File History of EP 2 663 325 (“EP-325-FH”)
`
`1064
`
`1065
`
`BMJ Publishing Group Ltd., Online First, BJO ONLINE, (Feb. 11,
`2009), https://bjo.bmj.com/onlinefirst.dtl
`[http://web.archive.org/web/20090212162702/https://bjo.bmj.com/o
`nlinefirst.dtl] (“Wayback-BJO-Online First”)
`
`BMJ Publishing Group Ltd., Review: Ranibizumab (Lucentis) In
`Neovascular Age-Related Macular Degeneration: Evidence From
`Clinical Trials, BRITISH J. OPHTHALMOLOGY (Dec. 2020),
`https://bjo.bmj.com/content/94/1/2.altmetrics (“BJO-Article
`Metrics”)
`
`-9-
`
`
`
`1066
`
`1067
`
`1068
`
`1069
`
`1070
`
`Press Release, Bayer, VEGF Trap-Eye Shows Positive Results in
`Phase II Study in Patients with Diabetic Macular Edema (Feb. 18,
`2010) (“Bayer (18-February-2010)”)
`
`Press Release, Bayer, Bayer HealthCare and Regeneron Announce
`Encouraging 32-Week Follow Up Results From A Phase 2 Study of
`VEGF Trap-Eye in Age-Related Macular Degeneration (Apr. 28,
`2008) (“Bayer (28-April-2008)”)
`
`Press Release, Regeneron, Enrollment Completed in Regeneron and
`Bayer Healthcare Phase 3 Studies of VEGF Trap-Eye in
`Neovascular Age-Related Macular Degeneration (Wet AMD) (Sept.
`14, 2009), https://newsroom.regeneron.com/news-releases/news-
`release-details/enrollment-completed-regeneron-and-bayer-
`healthcare-phase-3 (“Regeneron (14-September-2009)”)
`
`ClinicalTrials.gov, What Is ClinicalTrials.gov?, U.S. NAT’L
`LIBRARY MED. (Jan. 2018), https://www.clinicaltrials.gov/ct2/about-
`site/background (“Background-ClinicalTrials.gov”)
`
`Affidavit of Duncan Hall (Internet Archive Records Request
`Processor) Regarding Vascular Endothelial Growth Factor (VEGF)
`Trap-Eye: Investigation of Efficacy and Safety in Central Retinal
`Vein Occlusion (CRVO) (GALILEO), NCT01012973,
`ClinicalTrials.gov (Apr. 8, 2011); Vascular Endothelial Growth
`Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in
`Wet Age-Related Macular Degeneration (AMD) (VIEW1),
`NCT00509795, ClinicalTrials.gov (Apr. 8, 2011); and VEGF Trap-
`Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW 2),
`NCT00637377, ClinicalTrials.gov (Aug. 13, 2009), dated January 20,
`2021 (“Wayback-Affidavit-069”)
`
`1071
`
`Frank G Holz et al., VEGF Trap-Eye for Macular Oedema
`Secondary to Central Retinal Vein Occlusion: 6-Month Results of
`the Phase III GALILEO Study, 97 BRITISH J. OPHTHALMOLOGY 278
`(2013) (“Holz”)
`
`1072
`
`Janice M. Reichert, Antibody-Based Therapeutics To Watch In 2011,
`
`3 MABS 76 (2011) (“Reichert”)
`
`-10-
`
`
`
`1073
`
`Owen A. Anderson et al., Delivery of Anti-Angiogenic Molecular
`
`Therapies for Retinal Disease, 15 DRUG DISCOVERY TODAY
`
`272 (2010) (“Anderson”)
`
`1074
`
`1075
`
`Thomas A. Ciulla & Philip J. Rosenfeld, Antivascular Endothelial
`Growth Factor Therapy For Neovascular Age-Related Macular
`Degeneration, 20 CURRENT OPINION OPHTHALMOLOGY 158 (2009)
`(“Ciulla”)
`
`Zhang Ni & Peng Hui, Emerging Pharmacologic Therapies for Wet
`Age-Related Macular Degeneration, 223 OPHTHALMOLOGICA 401
`(2009) (“Ni”)
`
`1076 Marco A. Zarbin & Philip J. Rosenfeld, Pathway-Based Therapies
`for Age-Related Macular Degeneration: An Integrated Survey of
`Emerging Treatment Alternatives, 30 RETINA 1350 (2010)
`(“Zarbin”)
`
`1077
`
`Corporate Finance Institute, SEC Filings: Public Disclosures About
`Public Companies,
`https://corporatefinanceinstitute.com/resources/data/public-
`filings/sec-filings/ (last visited May 5, 2021) (“Corporate Finance
`Institute”)
`
`1078
`
`Carl W. Schneider, Nits, Grits, and Soft Information in SEC Filings,
`
`121 U. PA. L. REV. 254 (1972) (“Schneider”)
`
`1079
`
`Justin Kuepper, The Best Investment Information Sources: Using
`SEC Filings, Analyst Reports, and Company Websites, BALANCE
`(Jan. 13, 2021), https://www.thebalance.com/top-best-sources-of-
`investor-information-1979207 (“Kuepper”)
`
`1080
`
`Kristina Zucchi, EDGAR: Investors’ One-Stop-Shop For Company
`
`Filings, YAHOO!LIFE (Jan. 31, 2014),
`
`-11-
`
`
`
`https://www.yahoo.com/lifestyle/tagged/health/edgar-investors-one-
`
`stop-shop-170000800.html (“Zucchi”)
`
`1081
`
`Adam Hayes, SEC Filings: Forms You Need To Know,
`INVESTOPEDIA (Jan. 18, 2021),
`https://www.investopedia.com/articles/fundamental-analysis/08/sec-
`forms.asp (“Hayes”)
`
`1082
`
`Amino acid sequence alignment of SEQ ID NO:2 of the ’069 patent
`
`with SEQ ID NO:16 of the ’758 patent and SEQ ID NO:4 of Dix
`
`(“’069 Amino Acid Sequences”)
`
`1083
`
`1084
`
`1085
`
`1086
`
`Nucleotide sequence alignment of SEQ ID NO:1 of the ’069 patent
`with SEQ ID NO:15 of the ’758 patent and SEQ ID NO:3 of Dix
`(“’069 Nucleotide Sequences”)
`
`Declaration of Robert V. Cerwinski in Support of Motion for Pro
`Hac Vice Admission
`
`Declaration of Aviv A. Zalcenstein in Support of Motion for Pro Hac
`Vice Admission
`
`Declaration of Brigid M. Morris in Support of Motion for Pro Hac
`Vice Admission
`
`Dated: April 12, 2022
`
`
`
`Respectfully submitted,
`
`/Lora M. Green/
`
` Lora M. Green, Lead Counsel
` Reg. No. 43,541
`
`-12-
`
`
`
`CERTIFICATE OF SERVICE
`This is to certify that I caused to be served true and correct copy of the
`
`foregoing Exhibit List and EX1084-EX1086 on this 12th day of April 2022, on the
`
`Patent Owner at the correspondence address of the Patent Owner as follows:
`
`Deborah Fishman
`
`Deborah.fishman@arnoldporter.com
`
`David Cain
`
`David.Caine@arnoldporter.com
`
`Alice Sin Yu Ho
`
`Alice.ho@arnoldporter.com
`
`Victoria Reines
`
`Victoria.Reines@arnoldporter.com
`
`Jeremy Cobb
`
`Jeremy.Cobb@arnoldporter.com
`
`Daniel Reisner
`
`Daniel.Reisner@arnoldporter.com
`
`Matthew Wilk
`
`Matthew.Wilk@arnoldporter.com
`
`RegeneronEyleaIPRs@arnoldporter.com
`
`And to Counsel for Petitioner Mylan Pharmaceuticals in IPR2021-00880, as follows:
`
`Paul Molino
`
`paul@rmmslegal.com
`
`William A. Rakoczy
`
`wrakoczy@rmmslegal.com
`
`Heinz Salmen
`
`hsalmen@rmmslegal.com
`
`-13-
`
`
`
`Neil McLaughlin
`
`Teresa Rea
`
`Deborah Yellin
`
`Shannon Lentz
`
`nmclaughlin@rmmslegal.com
`
`trea@crowell.com
`
`dyellin@crowell.com
`
`slentz@crowell.com
`
`MYL_REG_IPR@rmmslegal.com
`
`Dated: April 12, 2022
`
`
`
`Respectfully submitted,
`
`/Lora M. Green/
`
` Lora M. Green, Lead Counsel
` Reg. No. 43,541
`
`-14-
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
